Because the isolated use of RBV promotes only transient viral HCV replication effects, since 2016 new reports have emerged using DAAs (IFN-free regimen) in HCV-associated glomerulopathies patients. The gene discussed is IFNA1; the disease is lipoprotein glomerulopathy.